Nagayama, D.; Kawana, H.; Watanabe, Y.; Horikawa, O.; Ohira, M.; Saiki, A.
Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes. J. Clin. Med. 2024, 13, 481.
https://doi.org/10.3390/jcm13020481
AMA Style
Nagayama D, Kawana H, Watanabe Y, Horikawa O, Ohira M, Saiki A.
Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes. Journal of Clinical Medicine. 2024; 13(2):481.
https://doi.org/10.3390/jcm13020481
Chicago/Turabian Style
Nagayama, Daiji, Hidetoshi Kawana, Yasuhiro Watanabe, Osamu Horikawa, Masahiro Ohira, and Atsuhito Saiki.
2024. "Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes" Journal of Clinical Medicine 13, no. 2: 481.
https://doi.org/10.3390/jcm13020481
APA Style
Nagayama, D., Kawana, H., Watanabe, Y., Horikawa, O., Ohira, M., & Saiki, A.
(2024). Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes. Journal of Clinical Medicine, 13(2), 481.
https://doi.org/10.3390/jcm13020481